RxDoctor Payments DataLook up a doctor →

Daniel Stupak, MD

Gastroenterology · Trumbull, CTNPI 1669664314

Payments from drug & device makers

$46,863in general payments, 2019–2025

Across 622 payments — averaging $75.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Phathom Pharmaceuticals, Inc.$10K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$7K
  • Ironwood Pharmaceuticals, Inc$5K
  • Nestle Healthcare Nutrition Inc.$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • plus $7K from 25 others

What the payments were for

  • Speaking & faculty fees$33,34071%
  • Travel & lodging$1220%
  • Food & beverage$13,35629%
  • Education$440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,863 in reported general payments places this provider in the 85th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$56,840
Medicare patients
267
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide145$160,578
XifaxanRifaximin14$45,176
IbsrelaTenapanor Hcl11$28,278
CreonLipase/Protease/Amylase12$16,970
TrulancePlecanatide20$15,849
MovantikNaloxegol Oxalate23$14,479
ClenpiqSod Picosulf/Mag Ox/Citric Ac39$6,859
Omeprazole314$4,709
Dexlansoprazole DrDexlansoprazole18$4,118
Sucralfate39$3,562
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates52$2,805
Famotidine60$2,187
Dicyclomine Hcl64$1,728
Ondansetron OdtOndansetron29$972
Pantoprazole Sodium117$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$13,415$177,548157 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$7,159$61,02434 claims
Ardelyx, Inc.Ibsrela$870$28,27811 claims
Redhill Biopharma Inc.Movantik$138$14,47923 claims
Ferring Pharmaceuticals Inc.Clenpiq$128$6,85939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →